Background and Purpose: Among the various calcium-induced biologic events occurring in hypoxic neurons, activation of the calcium-activated neutral proteinase (calpain) is a likely mediator of neuronal degeneration. In this study, we assessed the protective effects of a calpain inhibitor (Cbz-Val-Phe-H) against hypoxic damage to the neocortex.
It is widely held that increased intracellular calcium concentrations play a pivotal role in neuronal injury associated with hypoxia and ischemia.'2 However, the calcium-sensitive mechanisms responsible for this form of neuronal damage are not well understood and need to be elucidated. Understanding the roles of calcium-activated mechanisms will not only provide insights into the pathophysiology of hypoxic/ ischemic damage but will also facilitate improvement of therapeutic strategies for stroke.
Among the various calcium-sensitive biologic events in neurons, calcium-activated proteolysis via the neutral protease calpain is a likely candidate to participate in hypoxic/ischemic neuronal degeneration. Calpain is activated by an appropriate signal (elevated calcium), and sustained activation can exert deleterious effects, such as the proteolysis of key cytoskeletal proteins. Interest in this concept has recently been intensified by two sets of observations. First, the levels of several calpain substrates, including neurofilament protein, microtubuleassociated protein 2, spectrin, and calcium/calmodulindependent kinase II This particular calpain inhibitor was selected because of its membrane permeability,12 inhibitory characteristics,12 and proven ability to limit hypoxic damage in the hippocampus.9 The timing of the treatment was chosen based on previous studies by Arai et al14 in which calpain inhibitors were shown to block hypoxia-induced proteolysis. The delay to HD was measured in all slices (n=20 slices) for quantitative assessment. Statistical analyses of the two groups were performed using the unpaired Student's t test. A two-tailed value of P<.05 was considered to be statistically significant.
In a second set of experiments (n=56 slices), hypoxia was sustained for a fixed period of 15 minutes. The maximum amplitude of evoked potentials was obtained before and 1 hour after hypoxia. In these experiments, electrodes were repositioned after hypoxia to ensure the recording of maximal responses. A recovery ratio for synaptic responses was calculated by dividing the maximal posthypoxic response by the maximal prehypoxic response and multiplying this value by 100. The magnitudes of the recovery ratios were then compared among the different groups, which included slices treated with:
(1) ACSF only (control slices; n=26); (2) 
Results
Evoked responses recorded in layer III of the parietal cortex exhibited a waveform similar to those described previously.11"3 Cortical evoked responses were characterized by a small, short-latency, nonsynaptic response followed by a larger and longer-latency synaptic potential (Fig 1) . There was no apparent change in the shape or amplitude of the evoked waveform when ACSF containing 100 ,mol/L Cbz-Val-Phe-H was perfused, an observation that is consistent with the studies of Arlinghaus et al. 9 Transient hypoxia produced a characteristic sequence of changes in electrophysiological responses (Fig 1) . In most slices the synaptic responses declined first, followed later by an elimination of the nonsynaptic component. The complete loss of the nonsynaptic component coincided temporally with the occurrence of hypoxic depolarization. HD is a sudden, 10-to 17-mV shift of the DC potential. As shown in Fig 2, the average delays to HD in the control and the treated groups were virtually identical (1.71±0.09 and 1.88±0.09 minutes, respectively). In addition, the sequence of changes in the waveform during hypoxia was not affected by the drug treatment. After reoxygenation, the DC shift, the early nonsynaptic component, and the late synaptic component recovered in series. The DC potential recovered completely within 1 to 2 minutes in both groups. The time course, sequence, and magnitude of recovery of evoked potentials were similar in the Cbz-Val-Phe-H-treated and control groups.
In the second series of experiments, sustained hypoxia elicited the same set of intrahypoxic events as was observed in the first series of experiments. HD occurred within 1 to 3 minutes, and these depolarizations were sustained until the end of hypoxia in slices from each group. However, since hypoxic conditions were main- 50-and 100-,mol/L groups were significantly greater than that observed in the 20-,umol/L group (Fig 3) . Discussion Numerous studies have attempted to ameliorate ischemic and hypoxic neuronal damage by directly or indirectly limiting the elevation of intracellular calcium. The results of these studies have been mixed. 15 The limitations of this approach probably stem from the multiple sources that contribute to the elevation of intracellular calcium after sustained neuronal depolarization. Calcium can enter neurons through a variety of different channels; in addition, substantial levels of calcium can be released from intracellular stores. It is therefore quite difficult, if not impossible, to antagonize all of these different sources of calcium. The present experiments indicate that interventions that target mechanisms activated subsequent to intracellular calcium elevation represent a viable therapeutic strategy, and that calcium-activated proteolysis is a critical component of the pathophysiological cascade leading to neuronal death.
The rationale for investigating calpain inhibitors as potential therapeutic agents for neocortical damage is based on several recent observations. First, key cytoskeletal proteins (ie, spectrin, microtubule-associated protein 2, and neurofilament proteins) are preferred substrates for calpain. Second, substantial changes in the levels of these cytoskeletal proteins have been observed after hypoxia.310,14 Presumably, the uncontrolled proteolysis of any or all of these structural proteins would jeopardize continued cellular viability. Finally, calpain inhibitors have been shown to exert a neuroprotective effect against hypoxic and ischemic damage in the hippocampal neurons.8-10 The concept that treatment with a calpain inhibitor would be neuroprotective therefore has a good theoretical and mechanistic basis.
The in vitro neocortical slice model used here simulates in vivo hypoxic neuronal insults, which can incur considerable morbidity in the cerebral cortex. The slice preparation is particularly useful because it facilitates both the identification of mechanisms contributing to cellular damage and the evaluation of treatments designed to protect against such damage. A common feature of hypoxic responses in both in vitro and in vivo systems is the precipitous and profound depolarization observed during the intrahypoxic period, ie, HD. 
